Marc Guëll

Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey.

Seroba BioVentures Ltd (Seroba BioVentures) is a venture capital subsidiary of Kernel Management Partners Ltd founded in 2001 by Peter Sandys and Seamus O''Hara. The firm is headquartered in Dublin, Ireland.

TopiVert Ltd. develops topical treatments for inflammatory diseases of the eye and gut. Its application is used in the treatment of asthma, chronic obstructive pulmonary disease, and cystic fibrosis and other inflammatory diseases of the lungs. The company was founded by Eric Charles Meldrum in 2011 and is headquartered in London, the United Kingdom.

The Francis Crick Institute Ltd. operates as a biomedical discovery institute dedicated to understanding the scientific mechanisms of living things. The firms works helps to understand why disease develops and to find new ways to treat, diagnose, and prevent illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases. The company is headquartered in London, the United Kingdom.

Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland.

Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom.

Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain.

Cascara Ventures BVBA (Cascara Ventures) is a venture capital firm founded by Adriaan Hart de Ruijter in 2016. The firm is headquartered in Flemish Region, Belgium.

Calypso Biotech BV operates as immunotherapy biotech company. It develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Amsterdam, the Netherlands.

Sapreme Technologies BV operates as a biotech company that develops a platform technology to enable cytosolic delivery of macromolecule therapeutics. The company was founded by Ruben Postel in 2016 and is headquartered in Utrecht, the Netherlands.

TRex Bio Ltd. is a British company that provides biotechnology research and development services. The private company is based in London, UK. The company was founded in 2018 by Houman Ashrafian.

Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium.

AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021.

AstriVax NV, founded in 2022 by Hanne Callewaert, is a privately held Belgian company based in Leuven. AstriVax NV is located in the Biohub in Leuven and has secured a seed round of €30 million to continue building the vaccine technology. The Belgian company aims to address challenges in vaccinology with its innovative plug-and-play vaccine platform. AstriVax develops novel prophylactic and therapeutic vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various infectious diseases. Supported by well-known investors, AstriVax is committed to addressing real-world challenges in vaccinology. The company's mission is to fast forward the clinical development of game-changing vaccines, creating thermostable and durable vaccines that provide polyfunctional protection. AstriVax's portfolio includes indications such as yellow fever and rabies.

Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom.